



04-32-02

GAU 1617
CASE 4-30755B/DJ
RECEIVED
TECH CENTER 600/2900

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV041586449US</u> Express Mail Label Number	<u>4/26/02</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1617

BULLOCK ET AL.

Examiner: Kim, J.

APPLICATION NO: 10/072,516

FILED: FEBRUARY 6, 2002

FOR: ADDITIONAL THERAPEUTIC USE

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references are of record in parent Application No. 09/468,663 filed December 21, 1999, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

Also, copies of the other cited references are enclosed herewith.



The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

RECEIVED
MAY 3 2002
TECH CENTER 1600/2900

Respectfully submitted,



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134


Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6923

Date:

4/26/02

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30755B
APPLICATION NO.
10/072,516
APPLICANT
BULLOCK ET AL.
FILING DATE
FEBRUARY 6, 2002RECEIVED
MAY 03 2002
TECH CENTER 1600/2900
Group 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,225,428	7/6/93	Kraemer et al.	514/381		
	AB	5,399,578	3/21/95	Buehlmayer et al.	514/381		
	AC	5,565,469	10/15/96	Mihm et al.	514/300		
	AD	5,591,762	1/7/97	IHauel et al.	514/381		
	AE	5,683,997	11/4/97	Buehlmayer et al.	514/213		
	AF	5,684,015	11/4/97	Mederski et al.	514/303		
	AG	5,811,445	9/22/98	Corbier et al.	514/398		
	AH	5,352,687	10/4/94	Mueller et al.	514/341		
	AI	5,352,788(WO91/14679)	10/4/94	Bernhart et al.	544/231		
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	0 253 310	10/26/94	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	0 4 75 206	3/18/92	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AO	0 403 159	1/3/00	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP	0 420 237	3/6/96	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	0 459 136	12/27/96	EP			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Brink et al., "Localization of Angiotensin II Receptor Subtypes in the Human Atrium," J. Mol. Cell Cardiol., Vol. 28, pp. 1789-1799 (1996).
	AS	De Gasparo et al, "Angiotensin II receptor subtypes and cardiac function," European Heart Journal, Vol. 15, Supplement D, pp. 98-103 (1994).
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.